Adjunctive treatment of risperidone-induced hyperprolactinemia with aripiprazole: a randomized, double-blind, placebo-controlled study

Chinese Journal of New Drugs

Volumn 23, Issue 7, 2014, Pages 811-814

  Chen, Jing Xu ^a   Zhang, Rong Zhen ^a   Li, Wei ^a   Liu, Yan Hong ^a   Jiang, Li Yan ^a   Bian, Qing Tao ^a   Wang, Shao Li ^a   Yang, Fu De ^a  

^a BEIJING HUILONGGUAN HOSPITAL   (China)

Author keywords

Aripiprazole; Hyperprolactinemia; Risperidone; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; PLACEBO; PROLACTIN; RISPERIDONE;

ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; HUMAN; HYPERPROLACTINEMIA; MAJOR CLINICAL STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; POSITIVE AND NEGATIVE SYNDROME SCALE; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; UKU SIDE EFFECTS RATING SCALE;

EID: 84902126452     PISSN: 10033734     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. INDER W J, CASTLE D. Antipsychotic-induced hyperprolactinaemia[J]. Aust N Z J Psychiatry, 2011, 45(10): 830-837.
2. SUZUKI Y, SUGAI T, FUKUI N, et al. Differences in plasma prolactin levels in patients with schizophrenia treated on monotherapy with five second-generation antipsychotics[J]. Schizophr Res, 2013, 145(1-3): 116-119.
3. 2006, 15(8): 718-720.
4. 2008, 3(41): 169-171.
5. 2009, 42(4): 224-227.
6. CHEN J X, SU Y A, WANG S L, et al. Aripiprazole treatment of risperidone-induced hyperprolactinemia[J]. J Clin Psychiatry, 2009, 70(7): 1058-1059.
7. SHIM J C, SHIN J G, KELLY D L, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial[J]. Am J Psychiatry, 2007, 64(9): 1404-1410.
8. 1997, 7(6): 353-355.
9. 1993: 151-154.
10. LINGJAERDE O, AHLFORS U G, BECH P, et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients[J]. Acta Psychiatr Scand, 1987, 76(Suppl 334): 1-100.
11. 2003, 30(3): 160-163.
12. LEUCHT S, CIPRIANI A, SPINELI L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis[J]. Lancet, 2013, 382(9896): 951-962.
13. MONTEJO A L. Prolactin awareness: an essential consideration for physical health in schizophrenia[J]. Eur Neuropsychopharmacol, 2008, 18(Suppl): S108-S114.
14. KESSLER R M. Aripiprazole: what is the role of dopamine D2 receptor partial agonism?[J]. Am J Psychiatry, 2007, 164(9): 1310-1312.
15. INOUE T, DOMAE M, YAMADA K, et al. Effects of the novel antipsychotic agent 7-[4-[(2, 3-dichlorophenyl)-1-piperazinyl]butyoxy]-3, 4-dihydro-2 (1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland[J]. J Pharmacol Exp Ther, 1996, 277(1): 137-143.
16. 2008, 179(1): 63-66.